A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

Launched by CENTRE HOSPITALIER DE PAU · Nov 26, 2018

Keywords

ClinConnect Summary

This clinical trial, called "A New Breath for Malignant Hypertension," is focused on understanding a serious condition known as malignant hypertension, which is extremely high blood pressure that can cause significant damage to the body. The study aims to gather information from a large group of patients to learn more about how common this condition is, how it is currently treated, and to help improve the way it is diagnosed and managed. By creating a detailed database, researchers hope to develop better treatment plans and guidelines based on solid scientific evidence.

To participate in this study, individuals need to be between 65 and 74 years old and have been diagnosed with malignant hypertension, which means their blood pressure is extremely high (above 180/110) and is causing severe problems in their organs. Unfortunately, people under 18, those who cannot give consent, or those on dialysis cannot take part in the trial. If eligible, participants can expect to contribute to important research that could lead to improved care for others with this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Malignant hypertension according to the classic definition (Severe hypertension, above 180/110 associated with severe hypertensive retinopathy)
• • Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure
• Exclusion Criteria:
• • Age \< 18 years old
• • Patients who cannot freely give their consent, or patients who refuse to participate
• • Dialysis